These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7781201)

  • 1. Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies.
    Keller F
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S24-6. PubMed ID: 7781201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of binding in distribution of furosemide: where is nonrenal clearance?
    Branch RA
    Fed Proc; 1983 Apr; 42(6):1699-702. PubMed ID: 6832389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
    Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
    Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit.
    Pichette V; Geadah D; du Souich P
    Drug Metab Dispos; 1999 Jan; 27(1):81-5. PubMed ID: 9884313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saturable first-pass kinetics of propranolol.
    Keller F; Kunzendorf U; Walz G; Haller H; Offermann G
    J Clin Pharmacol; 1989 Mar; 29(3):240-5. PubMed ID: 2723110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evidence that urine composition affects the fraction of active furosemide in the nephrotic syndrome.
    Voelker JR; Jameson DM; Brater DC
    J Pharmacol Exp Ther; 1989 Sep; 250(3):772-8. PubMed ID: 2778714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver.
    Chiba M; Pang KS
    J Pharmacol Exp Ther; 1993 Aug; 266(2):492-9. PubMed ID: 8355186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of furosemide in functionally hepatectomized dogs.
    Verbeeck RK; Gerkens JF; Wilkinson GR; Branch RA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):479-83. PubMed ID: 7205627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative contribution of endogenous compounds and hypoalbuminemia in reducing the binding of furosemide in the plasma of newborn infants.
    Viani A; Pacifici GM
    Dev Pharmacol Ther; 1992; 18(1-2):39-43. PubMed ID: 1483361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of furosemide urinary elimination by nephrotic children.
    Prandota J
    Pediatr Res; 1983 Feb; 17(2):141-7. PubMed ID: 6828331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of rapid entry and a cellular binding space for salicylamide in perfused rat liver: a multiple indicator dilution study.
    Pang KS; Barker F; Schwab AJ; Goresky CA
    J Pharmacol Exp Ther; 1994 Jul; 270(1):285-95. PubMed ID: 8035326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.
    Rane A; Villeneuve JP; Stone WJ; Nies AS; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1978 Aug; 24(2):199-207. PubMed ID: 679597
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of ascorbic acid enhancement of the bioavailability and diuretic effect of furosemide.
    Lee MG; Chiou WL
    Drug Metab Dispos; 1998 May; 26(5):401-7. PubMed ID: 9571221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake.
    Baker M; Parton T
    Xenobiotica; 2007; 37(10-11):1110-34. PubMed ID: 17968739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic and intestinal first-pass effects of oltipraz in rats.
    Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
    Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of glycyrrhizin in normal and albumin-deficient rats.
    Koga K; Tomoyama M; Ohyanagi K; Takada K
    Biopharm Drug Dispos; 2008 Oct; 29(7):373-81. PubMed ID: 18548521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.